Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. D'Haens G, et al. Among authors: ochsenkuhn t. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9. Lancet. 2008. PMID: 18295023 Clinical Trial.
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkühn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ; Dutch 6-TG working group. de Boer NK, et al. Among authors: ochsenkuhn t. Digestion. 2006;73(1):25-31. doi: 10.1159/000091662. Epub 2006 Feb 21. Digestion. 2006. PMID: 16493198 Free article. Review.
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group. Abreu MT, et al. Among authors: ochsenkuhn t. Inflamm Bowel Dis. 2009 Jun;15(6):829-36. doi: 10.1002/ibd.20833. Inflamm Bowel Dis. 2009. PMID: 19130617 Clinical Trial.
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S. Jürgens M, et al. Among authors: ochsenkuhn t. Am J Gastroenterol. 2010 Aug;105(8):1811-9. doi: 10.1038/ajg.2010.95. Epub 2010 Mar 2. Am J Gastroenterol. 2010. PMID: 20197757
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude CJ, Vermeire S, Rutgeerts P. Feagan BG, et al. Among authors: ochsenkuhn t. Inflamm Bowel Dis. 2012 Jan;18(1):152-60. doi: 10.1002/ibd.21870. Epub 2011 Oct 29. Inflamm Bowel Dis. 2012. PMID: 22038857
92 results